Jason Ryan is Chairman of GeneDx’s Board of Directors. Jason held this same role at Sema4 prior to the company being renamed to GeneDx in January 2023. Jason began serving on Sema4’s Board of Directors in July 2021 and assumed the role of Executive Chair six months later.
Jason has held numerous executive leadership and board roles in diagnostics and therapeutics companies, with broad experience in scaling businesses from early stage through product launch and commercialization.
Jason most recently served as COO and CFO of Magenta Therapeutics (Nasdaq: MGTA), a company focused on developing novel medicines for patients with autoimmune diseases and blood cancers. Prior to that, Jason was CFO of Foundation Medicine, a transformative company in oncology molecular profiling. He helped lead that business through early development, its initial public offering, subsequent growth into a global commercial organization and ultimately, its acquisition by Roche Holdings (Nasdaq: RHHBY). Before Foundation Medicine, Jason led the finance and strategic planning efforts of several other high growth life science companies.
In addition to GeneDx, Jason currently serves on the board of directors of Singular Genomics (Nasdaq: OMIC) and previously served on the board of directors of ArcherDX, Inc. (acquired by Invitae Corporation (NYSE: NVTA)).
He began his career at Deloitte & Touche, where he earned a CPA, and he received a BA in Economics from Bates College and an MBA from Babson College.
What is Jason Ryan's net worth?
The estimated net worth of Jason Ryan is at least $1.50 million as of November 19th, 2024. Mr. Ryan owns 15,490 shares of GeneDx stock worth more than $1,500,826 as of April 23rd. This net worth approximation does not reflect any other investments that Mr. Ryan may own. Learn More about Jason Ryan's net worth.
How do I contact Jason Ryan?
The corporate mailing address for Mr. Ryan and other GeneDx executives is 333 Ludlow Street North Tower 8th Floor, Stamford CT, 06902. GeneDx can also be reached via phone at 800-298-6470 and via email at investors@sema4.com. Learn More on Jason Ryan's contact information.
Has Jason Ryan been buying or selling shares of GeneDx?
Jason Ryan has not been actively trading shares of GeneDx during the last quarter. Most recently, Jason Ryan sold 31,510 shares of the business's stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $71.28, for a transaction totalling $2,246,032.80. Following the completion of the sale, the director now directly owns 15,490 shares of the company's stock, valued at $1,104,127.20. Learn More on Jason Ryan's trading history.
Who are GeneDx's active insiders?
GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Kevin Feeley (CFO), Richard Pfenniger, Jr. (Director), Richard Pfenniger, Jr. (Director), Anthony Prentice (Insider), Isaac Ro (CFO), Jason Ryan (Chairman of the Board), Eric Schadt (CEO), and Katherine Stueland (CEO). Learn More on GeneDx's active insiders.
Are insiders buying or selling shares of GeneDx?
In the last year, GeneDx insiders bought shares 4 times. They purchased a total of 175,804 shares worth more than $3,771,670.44. In the last year, insiders at the sold shares 56 times. They sold a total of 2,133,918 shares worth more than $130,491,416.29. The most recent insider tranaction occured on April, 9th when CFO Kevin Feeley sold 15,516 shares worth more than $1,430,264.88. Insiders at GeneDx own 27.3% of the company.
Learn More about insider trades at GeneDx. Information on this page was last updated on 4/9/2025.
